How old is patient?
What happens if I overdose Paclitaxel Ebewe?
Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local, or emergency room immediately. Symptoms may include burning, numbness, or tingling; redness and/or sores on the mouth or lips; symptoms of infection (eg, fever, chills, persistent sore throat); unusual bruising or bleeding; unusual tiredness or weakness.
Proper storage of Paclitaxel Ebewe:
Paclitaxel Ebewe is usually handled and stored by a health care provider. Keep Paclitaxel Ebewe out of the reach of children and away from pets.
Overdose of Paclitaxel Ebewe in details
There is no known antidote for Paclitaxel Ebewe (Paclitaxel Ebewe) overdosage. The primary anticipated complications of overdosage would consist of bone marrow suppression, peripheral neurotoxicity, and mucositis. Overdoses in pediatric patients may be associated with acute ethanol toxicity.
What should I avoid while taking Paclitaxel Ebewe?
Drinking alcohol can increase certain side effects of Paclitaxel Ebewe.
This medicine can pass into body fluids (including urine, feces, vomit, semen, vaginal fluid). For at least 48 hours after you receive a dose, avoid allowing your body fluids to come into contact with your hands or other surfaces. Patients and caregivers should wear rubber gloves while cleaning up body fluids, handling contaminated trash or laundry or changing diapers. Wash hands before and after removing gloves. Wash soiled clothing and linens separately from other laundry.
Body fluids should not be handled by a woman who is pregnant or who may become pregnant. Use condoms during sexual activity to avoid exposure to body fluids.
Avoid being near people who are sick or have infections. Tell your doctor at once if you develop signs of infection.
Avoid activities that may increase your risk of bleeding or injury. Use extra care to prevent bleeding while shaving or brushing your teeth.
Do not receive a "live" vaccine while using Paclitaxel Ebewe. The vaccine may not work as well during this time, and may not fully protect you from disease. Live vaccines include measles, mumps, rubella (MMR), rotavirus, typhoid, yellow fever, varicella (chickenpox), zoster (shingles), and nasal flu (influenza) vaccine.
Paclitaxel Ebewe warnings
Anaphylaxis and severe hypersensitivity reactions characterized by dyspnea and hypotension requiring treatment, angioedema, and generalized urticaria have occurred in 2-4% of patients receiving Paclitaxel Ebewe in clinical trials. Fatal reactions have occurred in patients despite premedication. All patients should be pretreated with corticosteroids, diphenhydramine and H2 antagonists. Patients who experience severe hypersensitivity reactions to Paclitaxel Ebewe should not be rechallenged with the drug.
Bone marrow suppression (primarily neutropenia) is dose-dependent and is the dose-limiting toxicity. Neutrophil nadirs occurred at a median of 11 days. Paclitaxel Ebewe should not be administered to patients with baseline neutrophil counts of less than 1,500 cells/mm3 (<1,000 cells/mm3 for patients with KS). Frequent monitoring of blood counts should be instituted during Paclitaxel Ebewe treatment. Patients should not be re-treated with subsequent cycles of Paclitaxel Ebewe until neutrophils recover to a level >1,500 cells/mm3 (>1,000 cells/mm3 for patients with KS) and platelets recover to a level >100,000 cells/mm3.
Severe conduction abnormalities have been documented in <1% of patients during Paclitaxel Ebewe therapy and in some cases requiring pacemaker placement. If patients develop significant conduction abnormalities during Paclitaxel Ebewe infusion, appropriate therapy should be administered and continuous cardiac monitoring should be performed during subsequent therapy with Paclitaxel Ebewe.
Pregnancy: Paclitaxel Ebewe can cause fetal harm when administered to a pregnant woman. Administration of Paclitaxel Ebewe during the period of organogenesis to rabbits at doses of 3 mg/kg/day (about 0.2 the daily maximum recommended human dose on a mg/m2 basis) caused embryo and fetotoxicity, as indicated by intrauterine mortality, increased resorptions and increased fetal deaths. Maternal toxicity was also observed at this dose. No teratogenic effects were observed at 1 mg/kg/day (about 1/15 the daily maximum recommended human dose on a mg/m2 basis); teratogenic potential could not be assessed at higher doses due to extensive fetal mortality. There are no adequate and well controlled studies in pregnant women. If Paclitaxel Ebewe is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant.
What should I discuss with my healthcare provider before taking Paclitaxel Ebewe?
Some medical conditions may interact with Paclitaxel Ebewe. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:
- if you are pregnant, planning to become pregnant, or are breast-feeding
- if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement
- if you have allergies to medicines, foods, or other substances
- if you have a bacterial or viral infection, or HIV infection
- if you have a history of a heart attack or other heart problems (eg, irregular heartbeat), high or low blood pressure, liver or kidney problems, bone marrow problems, or blood problems (eg, low blood platelet or neutrophil counts)
- if you are undergoing radiation therapy
- if you have ever had an allergic reaction to an insect sting
Some MEDICINES MAY INTERACT with Paclitaxel Ebewe. Tell your health care provider if you are taking any other medicines, especially any of the following:
- Palifermin because if mouth or tongue sores develop, they may be more severe or last longer
- Azole antifungals (eg, itraconazole, ketoconazole), benzodiazepines (eg, midazolam, triazolam), buspirone, cimetidine, cisplatin, eletriptan, felodipine, fluoxetine, gemfibrozil, HIV protease inhibitors (eg, indinavir, ritonavir), HMG-CoA reductase inhibitors (eg, lovastatin, simvastatin), macrolides (eg, clarithromycin, erythromycin), nefazodone, repaglinide, rosiglitazone, sildenafil, or telithromycin because they may increase the risk of Paclitaxel Ebewe's side effects
- Carbamazepine, efavirenz, nevirapine, phenytoin, or rifampin because they may decrease Paclitaxel Ebewe's effectiveness
- Anticoagulants (eg, warfarin) or doxorubicin because the risk of their side effects may be increased by Paclitaxel Ebewe
This may not be a complete list of all interactions that may occur. Ask your health care provider if Paclitaxel Ebewe may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.
Paclitaxel Ebewe precautions
Patients should be pre-treated with corticosteroids, diphenhydramine and histamine antagonists (eg, ranitidine or cimetidine) prior to Paclitaxel Ebewe therapy since hypersensitivity reactions with dyspnea, hypotension and angioedema have been reported with Paclitaxel Ebewe.
Patients who experience severe hypersensitivity reactions to Paclitaxel Ebewe should not be rechallenged with the drug.
During Paclitaxel Ebewe therapy, continuous cardiac monitoring should be performed in patients with a previous history of conduction abnormalities since cardiac adverse effects (ie, myocardial infarction, symptoms of congestive heart failure) have been reported in patients receiving Paclitaxel Ebewe.
Paclitaxel Ebewe produces severe dose-limiting bone marrow depression. Therefore, regular blood counts should be performed in patients receiving Paclitaxel Ebewe and dosage should not be repeated until the neutrophil count is >1500 cells/mm3 (1000 cells/mm3 in patients with AIDS) and the platelet count is ≥100,000 cells/mm3.
Paclitaxel Ebewe is a cytotoxic anticancer drug and, as with other potentially toxic compounds, caution should be used in handling Paclitaxel Ebewe. The use of gloves is recommended. When Paclitaxel Ebewe comes in contact with the skin or mucous membranes, the skin or the affected areas should be washed immediately and thoroughly with soap and water.
It is dangerous to take Paclitaxel Ebewe, except under medical supervision.
Patients with Impaired Liver Function: Paclitaxel Ebewe should not be given to patients with severe hepatic dysfunction since it is metabolized mainly in the liver. Impaired liver function may therefore lead to accumulation of Paclitaxel Ebewe in plasma leading to increased adverse effects. However, as it has not been studied in patients with mild to moderately impaired liver function, caution should be observed when prescribing it in such patients.
Patients with Impaired Kidney Function: The pharmacokinetic parameters are not fully elucidated in patients with impaired kidney function. However, as Paclitaxel Ebewe undergoes extensive nonrenal clearance, it is not necessary to adjust the dose of Paclitaxel Ebewe in such patients.
Effects on the Ability to Drive or Operate Machinery: Paclitaxel Ebewe rarely interferes with sensory or motor functions and therefore, has no effects on the patient's ability to drive a vehicle or handle machinery.
Use in pregnancy & lactation: In animal experiments, administration of Paclitaxel Ebewe at IV doses of 3 mg/kg during organogenesis to rabbits was found to be maternotoxic and embryofetotoxic. Administration of Paclitaxel Ebewe to pregnant rats and rabbits produced abortions, decreased corpora lutea, a decrease in implantations and live fetuses, increased resorptions and embryofetal deaths. Although similar studies have not been done in pregnant women, Paclitaxel Ebewe should not be given to pregnant women and nursing mothers because of its mutagenic, teratogenic and carcinogenic potential. In general, use of contraception is recommended during therapy.
Excretion of Paclitaxel Ebewe into the human breast milk has not been studied. However, breastfeeding is not recommended during Paclitaxel Ebewe therapy because of its mutagenic, teratogenic and carcinogenic potential and risk of serious side effects in the infant.
Use in the
Elderly: It is not necessary to adjust the dose of Paclitaxel Ebewe in elderly patients since the safety and efficacy of Paclitaxel Ebewe are not altered in such patients, as compared to younger patients.
What happens if I miss a dose of Paclitaxel Ebewe?
Call your doctor for instructions if you miss an appointment for your Paclitaxel Ebewe protein-bound injection.
- DailyMed. "PACLITAXEL: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DrugBank. "paclitaxel". http://www.drugbank.ca/drugs/DB01229 (accessed September 17, 2018).
- MeSH. "Tubulin Modulators". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology